Lonza’s modest forecast for cell and gene therapies points to uncertainty about sector's future
As Lonza unveiled its four-year financial predictions on Tuesday, observers were left unsure about the CDMO’s cell and gene therapy (CGT) forecast. Nonetheless, they were …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
